Dimethylarginines, homocysteine metabolism, and cerebrospinal fluid markers for Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 31, Issue 4, 2012, Pages 751-758

  Arlt, Sönke ^a   Schwedhelm, Edzard ^a   Kölsch, Heike ^b   Jahn, Holger ^a   Linnebank, Michael ^c   Smulders, Yvo ^d   Jessen, Frank ^b   Böger, Rainer H ^a   Popp, Julius ^b,e  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Alzheimer's disease; asymmetric dimethylarginine; cerebrospinal fluid; homocysteine; S adenosylhomocysteine; S adenosylmethionine

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 6 N,N' DIMETHYLARGININE; AMYLOID BETA PROTEIN[1-42]; ARGININE; CREATININE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; AMINO ACID METABOLISM; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENDOTHELIAL DYSFUNCTION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; PRIORITY JOURNAL;

EID: 84866316965     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-112138     Document Type: Article

References (38)

1. Vallance P, Leone A, Calver A, Collier J, Moncada S (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339, 572-575.
2. Hawkins RD (1996) NO honey, I don't remember. Neuron 16, 465-467.
3. Arlt S, Schulze F, Eichenlaub M, Maas R, Lehmbeck JT, Schwedhelm E, Jahn H, Boger RH (2008) Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease. Dement Geriatr Cogn Disord 26, 58-64.
4. Selley ML (2003) Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging 24, 903-907.
5. Abe T, Tohgi H, Murata T, Isobe C, Sato C (2001) Reduction in asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci Lett 312, 177- 179.
6. Mulder C, Wahlund LO, Blomberg M, de Jong S, van Kamp GJ, Scheltens P, Teerlink T (2002) Alzheimer's disease is not associated with altered concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine in cerebrospinal fluid. J Neural Transm 109, 1203-1208.
7. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Bode-Boger SM (2006) ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 37, 2024-2029.
8. Brouns R, Marescau B, Possemiers I, Sheorajpanday R, De Deyn PP (2009) Dimethylarginine levels in cerebrospinal fluid of hyperacute ischemic stroke patients are associated with stroke severity. Neurochem Res 34, 1642-1649.
9. Martens-Lobenhoffer J, Sulyok E, Czeiter E, Buki A, Kohl J, Firsching R, Troger U, Bode-Boger SM (2007) Determination of cerebrospinal fluid concentrations of arginine and dimethylarginines in patients with subarachnoid haemorrhage. J Neurosci Methods 164, 155-160.
10. Schepers E, Barreto DV, Liabeuf S, Glorieux G, Eloot S, Barreto FC, Massy Z, Vanholder R (2011) Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin J Am Soc Nephrol 6, 1266-1273.
11. SwardfagerW, Lanctot K, Rothenburg L,Wong A, Cappell J, Herrmann N (2010) A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 68, 930-941.
12. Fuso A, Nicolia V, Cavallaro RA, Ricceri L, D'Anselmi F, Coluccia P, Calamandrei G, Scarpa S (2008) B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain Sadenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice. Mol Cell Neurosci 37, 731-746.
13. Zhang CE, Tian Q, Wei W, Peng JH, Liu GP, Zhou XW, Wang Q, Wang DW, Wang JZ (2008) Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol Aging 29, 1654-1665.
14. Linnebank M, Popp J, Smulders Y, Smith D, Semmler A, Farkas M, Kulic L, Cvetanovska G, Blom H, Stoffel-Wagner B, Kolsch H, Weller M, Jessen F (2010) S-adenosylmethionine is decreased in the cerebrospinal fluid of patients with Alzheimer's disease. Neurodegener Dis 7, 373-378.
15. Popp J, Lewczuk P, Linnebank M, Cvetanovska G, Smulders Y, Kolsch H, Frommann I, Kornhuber J, Maier W, Jessen F (2009) Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease. J Alzheimers Dis 18, 819- 828.
16. Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR (2000) Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 20, 1557-1564.
17. Boger RH, Lentz SR, Bode-Boger SM, Knapp HR, Haynes WG (2001) Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) 100, 161-167.
18. Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD, Sue LI, Beach TG (2003) Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol 23, 2055-2062.
19. Beach TG,Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, Pandya Y, Esh C, Connor DJ, Sabbagh M, Walker DG, RoherAE(2007) Circle ofWillis atherosclerosis: Association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol 113, 13-21.
20. Smith MA, Vasak M, Knipp M, Castellani RJ, Perry G (1998) Dimethylargininase, a nitric oxide regulatory protein, in Alzheimer disease. Free Radic Biol Med 25, 898-902.
21. StuhlingerMC,Tsao PS, Her JH, Kimoto M, BalintRF, Cooke JP (2001) Homocysteine impairs the nitric oxide synthase pathway: Role of asymmetric dimethylarginine. Circulation 104, 2569-2575.
22. Frey D, Braun O, Briand C, Vasak M, Grutter MG (2006) Structure of the mammalian NOS regulator dimethylarginine dimethylaminohydrolase: A basis for the design of specific inhibitors. Structure 14, 901-911.
23. Braun O, Knipp M, Chesnov S, Vasak M (2007) Specific reactions of S-nitrosothiols with cysteine hydrolases: A comparative study between dimethylargininase-1 and CTP synthetase. Protein Sci 16, 1522-1534.
24. Austin SA, Santhanam AV, Katusic ZS (2010) Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ Res 107, 1498-1502.
25. Colton CA, Vitek MP, Wink DA, Xu Q, Cantillana V, Previti ML, Van Nostrand WE, Weinberg JB, Dawson H (2006) NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 103, 12867-12872.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939- 944.
27. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189- 198.
28. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Boger RH (2005) Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 51, 1268- 1271.
29. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, Boger RH (2007) High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 851, 211-219.
30. Bode-Boger SM, Scalera F, Ignarro LJ (2007) The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther 114, 295-306.
31. Smith DE, Kok RM, Teerlink T, Jakobs C, Smulders YM (2006) Quantitative determination of erythrocyte folate vitamer distribution by liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med 44, 450-459.
32. Ubbink JB, Hayward Vermaak WJ, Bissbort S (1991) Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 565, 441-446.
33. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Burger K, Hampel H, Frolich L,Wolf S, Prinz B, Jahn H, Luckhaus C, Perneczky R, Hull M, Schroder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kolsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J (2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: A multicenter study. Mol Psychiatry 15, 138-145.
34. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31, 545-548.
35. Sontag E, Nunbhakdi-Craig V, Sontag JM, Diaz-Arrastia R, Ogris E, Dayal S, Lentz SR, Arning E, Bottiglieri T (2007) Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci 27, 2751-2759.
36. Sontag JM, Nunbhakdi-Craig V, Montgomery L, Arning E, Bottiglieri T, Sontag E (2008) Folate deficiency induces in vitro and mouse brain region-specific downregulation of leucine carboxyl methyltransferase-1 and protein phosphatase 2A B(alpha) subunit expression that correlate with enhanced tau phosphorylation. J Neurosci 28, 11477-11487.
37. de laTorre JC (2002) Alzheimer disease as a vascular disorder: Nosological evidence. Stroke 33, 1152-1162.
38. Beach TG, Monsell SE, Phillips LE, KukullW(2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 71, 266-273.